Onco-Innovations' Inka Health Advances Real-World Oncology Research

Onco-Innovations Limited announced a groundbreaking study via its subsidiary, Inka Health Corp. The research, featured in JAMA Network Open, addresses key biases in real-world oncology research using Quantitative Bias Analysis (QBA). Sponsored by Roche, this study introduces methods for aligning the validity of clinical comparisons drawn from real-world data, an area gaining traction with regulatory bodies.

Spearheaded by Alind Gupta, the study utilizes real-world data to emulate treatment comparisons in advanced non-small cell lung cancer. Findings reveal that QBA effectively aligns these comparisons with randomized trial outcomes, enhancing study reliability.

The study holds significance as agencies like the FDA and EMA increasingly incorporate real-world evidence into their assessments. Onco-Innovations plans to integrate QBA into Inka's SynoGraph platform, potentially revolutionizing access to innovative cancer treatments.